WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...

The City of Toronto launched a new system for online recreation and cultural activities registration, facility bookings and memberships on November 6, 2024. Registration for recreation programs by ...

Little Leo Moley from Co Down needs multiple support therapies due to a rare genetic disorder, but his family never imagined that a Shetland pony would become part of his weekly therapeutic ...

Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts ...

PF Transfer Process Online: The Employees’ Provident Fund Organisation (EPFO) has introduced significant changes to simplify the transfer process of PF accounts when employees change jobs. This is ...

The EPFO said more than 1.25 crore subscribers will get the benefit of the new simplified process for transfer of PF account on change of jobs. As of now, the transfer of PF accumulations is done ...

Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude's efforts ...

The simplified EPF account transfer process is expected to benefit over 1.25 crore EPFO members. With this streamlined mechanism in place, EPFO anticipates handling seamless EPF account transfers of ...

Employees' Provident Fund Organisation has made it easier to transfer PF accounts. Now, employer approval is not needed in most cases. This change speeds up the transfer process. It benefits over 1.25 ...

EPFO has removed the requirement of approval of all transfer claims at the destination office by launching a revamped form 13 software functionality The Tribune, now published from Chandigarh ...

We are also delighted to report initial preclinical data from our selective KAT6A degrader discovery program. These data demonstrate that selectively degrading KAT6A results in robust anti-cancer ...

Prelude Therapeutics has announced new preclinical data on its first-in-class SMARCA2 degrader, PRT3789, and its selective KAT6A degraders at the AACR Annual Meeting. PRT3789 shows potential as a ...